Novo Nordisk A/S (0QIU.IL)
IOB · DKK · Healthcare · Biotechnology
DKK 259.65 (-0.29%) as of
Key statistics
- Market cap
- 1.09T
- P/E (TTM)
- 17.47
- EPS (TTM)
- 14.86
- Dividend yield
- 1.04%
- 52-week range
- 225.00 – 409.90
- Beta
- 0.21
- Revenue (TTM)
- 201.33B
- Profit margin
- 33.40%
- Volume
- 80.09k
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bagsvaerd, Denmark
- Employees
- 59,337
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.